Glucose-responsive insulin by molecular and physical design

Glucose-responsive insulin is a therapeutic that modulates its potency, concentration or dosing relative to a patient’s dynamic glucose concentration. This Perspective summarizes some of the recent accomplishments in this field as well as discussing new computational algorithms that may aid in the development of such therapeutics. The concept of a glucose-responsive insulin (GRI) has been a recent objective of diabetes technology. The idea behind the GRI is to create a therapeutic that modulates its potency, concentration or dosing relative to a patient's dynamic glucose concentration, thereby approximating aspects of a normally functioning pancreas. From the perspective of the medicinal chemist, the GRI is also important as a generalized model of a potentially new generation of therapeutics that adjust potency in response to a critical therapeutic marker. The aim of this Perspective is to highlight emerging concepts, including mathematical modelling and the molecular engineering of insulin itself and its potency, towards a viable GRI. We briefly outline some of the most important recent progress toward this goal and also provide a forward-looking viewpoint, which asks if there are new approaches that could spur innovation in this area as well as to encourage synthetic chemists and chemical engineers to address the challenges and promises offered by this therapeutic approach.

[1]  Bernhard O Boehm,et al.  Insulin analogues , 2019, Reactions Weekly.

[2]  David Lee,et al.  Principles and methods of testing finite state machines-a survey , 1996, Proc. IEEE.

[3]  S. Asher,et al.  Polymerized colloidal crystal hydrogel films as intelligent chemical sensing materials , 1997, Nature.

[4]  J. Mayer,et al.  Pursuit of a perfect insulin , 2016, Nature Reviews Drug Discovery.

[5]  B. Zinman,et al.  Insulins today and beyond , 2001, The Lancet.

[6]  Akira Matsumoto,et al.  A synthetic approach toward a self-regulated insulin delivery system. , 2012, Angewandte Chemie.

[7]  Daniel G Anderson,et al.  Injectable nano-network for glucose-mediated insulin delivery. , 2013, ACS nano.

[8]  A. Cerami,et al.  A glucose-controlled insulin-delivery system: semisynthetic insulin bound to lectin. , 1979, Science.

[9]  H. Tager,et al.  Perturbation of insulin-receptor interactions by intramolecular hormone cross-linking. Analysis of relative movement among residues A1, B1, and B29. , 1989, The Journal of biological chemistry.

[10]  D. Hall,et al.  An improved class of sugar-binding boronic acids, soluble and capable of complexing glycosides in neutral water. , 2006, Journal of the American Chemical Society.

[11]  Binghe Wang,et al.  A detailed examination of boronic acid–diol complexation , 2002 .

[12]  J. Buse,et al.  Bio-Inspired Synthetic Nanovesicles for Glucose-Responsive Release of Insulin , 2014, Biomacromolecules.

[13]  N A Peppas,et al.  Glucose-sensitivity of glucose oxidase-containing cationic copolymer hydrogels having poly(ethylene glycol) grafts. , 2000, Journal of Controlled Release.

[14]  Benjamin C. Tang,et al.  Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates , 2015, Proceedings of the National Academy of Sciences.

[15]  Buddy D. Ratner,et al.  Glucose sensitive membranes for controlled delivery of insulin: Insulin transport studies , 1985 .

[16]  N. Peppas.  Is there a future in glucose-sensitive, responsive insulin delivery systems? , 2004 .

[17]  Kun Huang,et al.  Design of an Active Ultrastable Single-chain Insulin Analog , 2008, Journal of Biological Chemistry.

[18]  Benjamin C. Tang,et al.  Managing diabetes with nanomedicine: challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[19]  T. Hoeg-Jensen.  Preparation and Screening of Diboronate Arrays for Identification of Carbohydrate Binders , 2004 .

[20]  A. Wendel,et al.  A T cell-dependent experimental liver injury in mice inducible by concanavalin A. , 1992, The Journal of clinical investigation.

[21]  I. Vetter,et al.  2-nitroveratryl as a photocleavable thiol-protecting group for directed disulfide bond formation in the chemical synthesis of insulin. , 2014, Chemistry.

[22]  P. Home.  Insulin glargine: the first clinically useful extended-acting insulin in half a century? , 1999, Expert opinion on investigational drugs.

[23]  Gary Walsh,et al.  Therapeutic insulins and their large-scale manufacture , 2005, Applied Microbiology and Biotechnology.

[24]  Benjamin C. Tang,et al.  Glucose-responsive microgels integrated with enzyme nanocapsules for closed-loop insulin delivery. , 2013, ACS nano.

[25]  F. Marken,et al.  Exploiting the reversible covalent bonding of boronic acids: recognition, sensing, and assembly. , 2013, Accounts of chemical research.

[26]  Binghe Wang,et al.  The relationship among pKa, pH, and binding constants in the interactions between boronic acids and diols—it is not as simple as it appears , 2004 .

[27]  G. Grodsky,et al.  Release of insulin from pH-sensitive poly(ortho esters)☆ , 1990 .

[28]  S. Havelund,et al.  Reversible insulin self-assembly under carbohydrate control. , 2005, Journal of the American Chemical Society.

[29]  M. Weiss,et al.  Mini-proinsulin and mini-IGF-I: homologous protein sequences encoding non-homologous structures. , 1998, Journal of molecular biology.

[30]  A Boutayeb,et al.  A critical review of mathematical models and data used in diabetology , 2006, Biomedical engineering online.

[31]  T. Pieber,et al.  Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies , 2007, Diabetes, obesity & metabolism.

[32]  Claudio Cobelli,et al.  GIM, Simulation Software of Meal Glucose—Insulin Model , 2007, Journal of diabetes science and technology.

[33]  J. B. Christensen,et al.  Arylboronic acids: A diabetic eye on glucose sensing , 2012 .

[34]  K. Drejer.  The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. , 1992, Diabetes/metabolism reviews.

[35]  R. Langer,et al.  Enzymatically controlled drug delivery. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. King,et al.  A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations , 2011, Diabetes, obesity & metabolism.

[37]  C. Cobelli,et al.  Artificial Pancreas: Past, Present, Future , 2011, Diabetes.

[38]  M. Weiss,et al.  Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering , 2011, Annals of the New York Academy of Sciences.

[39]  C. Cobelli,et al.  In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes , 2009, Journal of diabetes science and technology.

[40]  T. James,et al.  Glucose sensing via aggregation and the use of "knock-out" binding to improve selectivity. , 2013, Journal of the American Chemical Society.

[41]  A. K. Yatsimirsky,et al.  Substituent effects and pH profiles for stability constants of arylboronic acid diol esters. , 2013, The Journal of organic chemistry.

[42]  D. Flora,et al.  A synthetic route to human insulin using isoacyl peptides. , 2014, Angewandte Chemie.

[43]  Svend Havelund,et al.  Biochemical and Physiological Properties of a Novel Series of Long-Acting Insulin Analogs Obtained by Acylation with Cholic Acid Derivatives , 2006, Pharmaceutical Research.

[44]  Daniel G. Anderson,et al.  Engineering synthetically modified insulin for glucose-responsive diabetes therapy , 2015, Expert review of endocrinology & metabolism.

[45]  Daniel G. Anderson,et al.  Smart approaches to glucose-responsive drug delivery , 2015, Journal of drug targeting.

[46]  P. Kurtzhals,et al.  The cobalt(III)-insulin hexamer is a prolonged-acting insulin prodrug. , 1995, Journal of pharmaceutical sciences.

[47]  Dale G. Drueckhammer,et al.  Computer-Guided Design in Molecular Recognition: Design and Synthesis of a Glucopyranose Receptor This work was supported by the National Institutes of Health (grant DK5523402). , 2001, Angewandte Chemie.

[48]  J. Keasling,et al.  Synthesis: A constructive debate , 2012, Nature.

[49]  E. Nishimura,et al.  Receptor-isoform-selective insulin analogues give tissue-preferential effects. , 2011, The Biochemical journal.

[50]  S. Shinkai,et al.  The Molecular Recognition of Saccharides. Complexation of Boronic Acids with Saccharides. Fluorescent Sensors. Modular Fluorescent Sensors. Other Types of Sensor. Other Systems for Saccharide Recognition. , 2006 .

[51]  E J Dodson,et al.  X-ray analysis of the single chain B29-A1 peptide-linked insulin molecule. A completely inactive analogue. , 1991, Journal of molecular biology.

[52]  Isao Shinohara,et al.  Glucose Induced Permeation Control of Insulin through a Complex Membrane Consisting of Immobilized Glucose Oxidase and a Poly(amine) , 1984 .

[53]  Claudio Cobelli,et al.  Meal Simulation Model of the Glucose-Insulin System , 2007, IEEE Transactions on Biomedical Engineering.

[54]  T. James,et al.  A d-glucose selective fluorescent assay , 2002 .

[55]  Gili Bisker,et al.  A Pharmacokinetic Model of a Tissue Implantable Insulin Sensor , 2015, Advanced healthcare materials.

[56]  S. Heller,et al.  Insulin's 85th anniversary--An enduring medical miracle. , 2007, Diabetes research and clinical practice.

[57]  D. Russell-Jones,et al.  Insulin analogues: an example of applied medical science , 2009, Diabetes, obesity & metabolism.

[58]  L. Schäffer,et al.  Total Synthesis of desB30 Insulin Analogues by Biomimetic Folding of Single‐Chain Precursors , 2008, Chembiochem : a European journal of chemical biology.

[59]  S. Havelund,et al.  Insulins with built‐in glucose sensors for glucose responsive insulin release , 2005, Journal of peptide science : an official publication of the European Peptide Society.

[60]  R S Parker,et al.  The intravenous route to blood glucose control. , 2001, IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society.

[61]  Brian J. Smith,et al.  Protective hinge in insulin opens to enable its receptor engagement , 2014, Proceedings of the National Academy of Sciences.

[62]  D. Owens,et al.  Insulin analogues , 1997, The Lancet.

[63]  J Kost,et al.  Glucose-sensitive polymeric matrices for controlled drug delivery. , 1993, Clinical materials.

[64]  Francis J. Doyle,et al.  Robust H∞ glucose control in diabetes using a physiological model , 2000 .

[65]  U. Ribel,et al.  Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin , 2012, Pharmaceutical Research.

[66]  D. Edgerton,et al.  Changes in Glucose and Fat Metabolism in Response to the Administration of a Hepato-Preferential Insulin Analog , 2014, Diabetes.

[67]  J. Mayer,et al.  Chemical synthesis of insulin analogs through a novel precursor. , 2014, ACS chemical biology.

[68]  G. Springsteen,et al.  Alizarin Red S. as a general optical reporter for studying the binding of boronic acids with carbohydrates. , 2001, Chemical communications.

[69]  Colin Camerer.  : Past , Present , Future , 2003 .

[70]  M. Weiss,et al.  Fully convergent chemical synthesis of ester insulin: determination of the high resolution X-ray structure by racemic protein crystallography. , 2013, Journal of the American Chemical Society.

[71]  R.S. Parker,et al.  A model-based algorithm for blood glucose control in Type I diabetic patients , 1999, IEEE Transactions on Biomedical Engineering.

[72]  E. Redwan,et al.  Cell factories for insulin production , 2014, Microbial Cell Factories.

[73]  E. Giralt,et al.  S-Phenylacetamidomethyl (Phacm): an orthogonal cysteine protecting group for Boc and Fmoc solid-phase peptide synthesis strategies , 1995 .

[74]  J. Mayer,et al.  Concise synthetic routes to human insulin. , 2013, Organic letters.

[75]  J. Mayer,et al.  Insulin structure and function. , 2007, Biopolymers.

[76]  Andrzej M. Brzozowski,et al.  How insulin engages its primary binding site on the insulin receptor , 2013, Nature.

[77]  S. Friedman.  Functional Synthetic Receptors Edited by Thomas Schrader (Philipps-Universität Marburg) and Andrew D. Hamilton (Yale University). Wiley-VCH Verlag GbH & Co. KgaA: Weinheim. 2005. xii + 428 pp. $180.00. ISBN 3-527-30655-2. , 2005 .

[78]  Thomas Schrader,et al.  Functional Synthetic Receptors , 2005 .

[79]  J. Tait,et al.  Challenges and opportunities. , 1996, Journal of psychiatric and mental health nursing.

[80]  Francis J. Doyle,et al.  Preparation and dynamic response of cationic copolymer hydrogels containing glucose oxidase , 2000 .

[81]  John Thomas Sorensen,et al.  A physiologic model of glucose metabolism in man and its use to design and assess improved insulin therapies for diabetes , 1985 .

[82]  U. Ribel,et al.  Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. , 1995, The Biochemical journal.

[83]  L. Arleth,et al.  Perfluoroalkyl chains direct novel self-assembly of insulin. , 2012, Langmuir : the ACS journal of surfaces and colloids.

[84]  T. Sølling,et al.  Ortho-substituted aryl monoboronic acids have improved selectivity for d-glucose relative to d-fructose and l-lactate , 2011 .

[85]  H. Landahl,et al.  [Further studies on the dynamic aspects of insulin release in vitro with evidence for a two-compartmental storage system]. , 1969, Acta diabetologica latina.

[86]  S. Shinkai,et al.  Boronic Acids in Saccharide Recognition , 2006 .